Gestational evaluation in patients with Dermatomyositis/Polymyositis

• Grant number: 11/15517-3
• Support Opportunities: Scholarships in Brazil - Scientific Initiation
• Start date: February 01, 2012
• End date: January 31, 2013
• Field of knowledge: Health Sciences - Medicine - Medical Clinics
• Principal Investigator: Samuel Katsuyuki Shinjo
• Grantee: Larissa Sayuri Missumi
• Host Institution: Hospital das Clínicas da Faculdade de Medicina da USP (HCFMUSP). Secretaria da Saúde (São Paulo - Estado). São Paulo , SP, Brazil

Abstract

Idiopathic inflammatory myopathies (IIM) are a heterogeneous group of chronic autoimmune diseases, systemic, associated with high morbidity and functional disability. Concerning the clinical and histopathological features, the MII can be classified as Polymyositis (PM), Dermatomyositis (DM), juvenile Dermatomyositis, inclusion body myositis, myositis associated with malignancy, and myositis associated with other collagen diseases. Until now, the studies in the literature that describe pregnancy in DM/PM are mainly limited to case reports or series. This is because DM/PM: a) is a rare systemic autoimmune disease; b) affects mainly individuals outside the age of fertility (45~55 years old). Consequently, evaluation and behavior of gestation in MII activity or remission of the disease and vice-versa is still controversial in the literature. Therefore, the few studies of pregnancy in DM/PM have motivated us to extend the approach of this topic in our population of DM/PM Service followed at tertiary composed of large samples.(AU)

Scientific publications

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

LARISSA SAYURI MISSUMI; FERNANDO HENRIQUE CARLOS DE SOUZA; JOELMA QUEIROZ ANDRADE; SAMUEL KATSUYUKI SHINJO. Desfechos da gestação em pacientes com dermatomiosite e polimiosite. REVISTA BRASILEIRA DE REUMATOLOGIA, v. 55, n. 2, p. 95-102, 2015-04-00. (11/15517-3)